The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Sulfonylurea Inadequacy
Abstract
OBJECTIVE—To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is inadequate in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS—Glycemic control, hypoglycemia, and body weight were monitored over 6 years in 826 patients with newly diagnosed type 2 diabetes in 8 of 23 U.K. Prospective Diabetes Study (UKPDS) centers that used a modified protocol. Patients were randomly allocated to a conventional glucose control policy, primarily with diet (n = 242) or an intensive policy with insulin alone (n = 245), as in the main study. However, for patients randomized to an intensive policy with sulfonylurea (n = 339), insulin was added automatically if the fasting plasma glucose remained >108 mg/dl (6.0 mmol/l) despite maximal sulfonylurea doses. RESULTS—Over 6 years, ∼53% of patients allocated to treatment with sulfonylurea required additional insulin therapy. Median HbA1c in the sulfonylurea ± insulin group was significantly lower (6.6%, interquartile range [IQR] 6.0–7.6) than in the group taking insulin alone (7.1%, IQR 6.2–8.0; P = 0.0066), and significantly more patients in the sulfonylurea ± insulin group had an HbA1c <7% (47 vs. 35%, respectively; P = 0.011). Weight gain was similar in the intensive therapy groups, but major hypoglycemia occurred less frequently over all in the sulfonylurea (± insulin) group compared with the insulin alone group (1.6 vs. 3.2% per annum, respectively; P = 0.017). CONCLUSIONS—Early addition of insulin when maximal sulfonylurea therapy is inadequate can significantly improve glycemic control without promoting increased hypoglycemia or weight gain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 10
- UKPDS Group: UK Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83–88 1995 · DOI · Paper page
- UKPDS Group: UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136–145 1996 · DOI · Paper page
- Turner RC, Holman RR, Matthews DR: Sulphonylurea failure and inadequacy: “non-insulin diabetes mellitus”. In Proceedings of the 13th IDF Conference, Hamilton Island, Australia, 26–28 1988. Cameron D, Colagiuri S, Heding L, Kuhl C, Ma A, Mortimer R, Eds. Causeway Bay, Hong Kong, Excerpta Medica Asia, 1989
- UKPDS Group: UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890, 1991 · DOI · Paper page
- Johnson JL, Wolf SL, Kabadi UM: Efficacy of insulin and sulphonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebo-controlled trials. Arch Intern Med 156:259–264, 1996 · DOI
- Holman RR, Turner RC: A practical guide to basal and prandial insulin therapy. Diabetic Medicine 5:45–53, 1985 · DOI
- UKPDS Group: UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544, 1994 · DOI
- Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 21:1052–1057, 1998 · DOI
- Holman RR, Steemson J, Turner RC: Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med 4:457–462, 1987 · DOI
- Shank ML, Prato SD, DeFronzo RA: Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in MIDDM. Diabetes 44:165–172, 1995 · doi:10.2337/diabetes.44.2.165
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationBarriers to diabetes management: patient and provider factors
Nam, S., Chesla, C., Stotts, N. A., Kroon, L., & Janson, S. L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.002 · Cited by 680
Metadata
- Authors
- Wright, A., Burden, A. C. F., Paisey, R. B., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-02-01
- Volume
- 25
- Issue
- 2
- Pages
- 330-336
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1996441843
- Cited by
- 556
- References
- 4
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Update notices
- correction (2002-07-01)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulfonylurea Inadequacy. https://app.cochat.ai/papers/10.2337/diacare.25.2.330
- The paper
- Wright, A., Burden, A. C. F., Paisey, R. B., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group. (2002). Sulfonylurea Inadequacy. Diabetes Care. https://doi.org/10.2337/diacare.25.2.330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.